Santen Pharmaceutical Co., Ltd. (4536.T)
JPY 1548.0
(-0.51%)
JPY 1548.0
(-0.51%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 301.96 Billion JPY | 8.22% |
| 2022 | 279.03 Billion JPY | 4.8% |
| 2021 | 266.25 Billion JPY | 6.67% |
| 2020 | 249.6 Billion JPY | 3.33% |
| 2019 | 241.55 Billion JPY | 3.22% |
| 2018 | 234.02 Billion JPY | 4.04% |
| 2017 | 224.94 Billion JPY | 12.98% |
| 2016 | 199.09 Billion JPY | 1.95% |
| 2015 | 195.29 Billion JPY | 20.68% |
| 2014 | 161.83 Billion JPY | 8.86% |
| 2013 | 148.66 Billion JPY | 24.86% |
| 2012 | 119.06 Billion JPY | 4.06% |
| 2011 | 114.41 Billion JPY | 3.25% |
| 2010 | 110.81 Billion JPY | 0.2% |
| 2009 | 110.59 Billion JPY | 8.83% |
| 2008 | 101.61 Billion JPY | -1.72% |
| 2007 | 103.39 Billion JPY | 2.89% |
| 2006 | 100.48 Billion JPY | 2.12% |
| 2005 | 98.39 Billion JPY | 6.15% |
| 2004 | 92.69 Billion JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 74.77 Billion JPY | -5.51% |
| 2023 Q3 | 77.02 Billion JPY | 4.92% |
| 2023 Q2 | 73.41 Billion JPY | 1.42% |
| 2023 Q1 | 72.38 Billion JPY | -8.66% |
| 2023 FY | 301.96 Billion JPY | 8.22% |
| 2023 Q4 | 79.13 Billion JPY | 2.73% |
| 2022 Q1 | 65.53 Billion JPY | -6.99% |
| 2022 FY | 279.03 Billion JPY | 4.8% |
| 2022 Q4 | 79.25 Billion JPY | 11.82% |
| 2022 Q3 | 70.87 Billion JPY | 11.82% |
| 2022 Q2 | 63.38 Billion JPY | -3.28% |
| 2021 Q3 | 67.04 Billion JPY | 5.13% |
| 2021 Q1 | 64.98 Billion JPY | -4.18% |
| 2021 Q2 | 63.77 Billion JPY | -1.87% |
| 2021 Q4 | 70.45 Billion JPY | 5.09% |
| 2021 FY | 266.25 Billion JPY | 6.67% |
| 2020 Q1 | 57.56 Billion JPY | -2.81% |
| 2020 Q4 | 67.81 Billion JPY | 7.85% |
| 2020 Q3 | 62.88 Billion JPY | 2.51% |
| 2020 Q2 | 61.34 Billion JPY | 6.56% |
| 2020 FY | 249.6 Billion JPY | 3.33% |
| 2019 Q4 | 59.22 Billion JPY | -6.8% |
| 2019 Q3 | 63.55 Billion JPY | 6.56% |
| 2019 Q2 | 59.63 Billion JPY | 0.85% |
| 2019 Q1 | 59.13 Billion JPY | -2.76% |
| 2019 FY | 241.55 Billion JPY | 3.22% |
| 2018 Q4 | 60.81 Billion JPY | 3.31% |
| 2018 FY | 234.02 Billion JPY | 4.04% |
| 2018 Q2 | 57.86 Billion JPY | 2.44% |
| 2018 Q1 | 56.48 Billion JPY | 0.24% |
| 2018 Q3 | 58.86 Billion JPY | 1.74% |
| 2017 Q2 | 54.82 Billion JPY | -2.01% |
| 2017 Q1 | 55.94 Billion JPY | 15.53% |
| 2017 Q3 | 57.81 Billion JPY | 5.46% |
| 2017 Q4 | 56.35 Billion JPY | -2.54% |
| 2017 FY | 224.94 Billion JPY | 12.98% |
| 2016 Q2 | 47.82 Billion JPY | -4.37% |
| 2016 Q4 | 48.42 Billion JPY | -8.34% |
| 2016 FY | 199.09 Billion JPY | 1.95% |
| 2016 Q1 | 50 Billion JPY | 8.5% |
| 2016 Q3 | 52.83 Billion JPY | 10.48% |
| 2015 Q4 | 46.08 Billion JPY | -10.22% |
| 2015 FY | 195.29 Billion JPY | 20.68% |
| 2015 Q1 | 47.97 Billion JPY | 6.64% |
| 2015 Q2 | 49.89 Billion JPY | 4.01% |
| 2015 Q3 | 51.33 Billion JPY | 2.87% |
| 2014 Q3 | 44.91 Billion JPY | 17.45% |
| 2014 Q4 | 44.98 Billion JPY | 0.16% |
| 2014 FY | 161.83 Billion JPY | 8.86% |
| 2014 Q1 | 33.68 Billion JPY | -15.2% |
| 2014 Q2 | 38.24 Billion JPY | 13.54% |
| 2013 FY | 148.66 Billion JPY | 24.86% |
| 2013 Q1 | 34.31 Billion JPY | 11.99% |
| 2013 Q2 | 34.94 Billion JPY | 1.85% |
| 2013 Q3 | 39.68 Billion JPY | 13.55% |
| 2013 Q4 | 39.71 Billion JPY | 0.09% |
| 2012 FY | 119.06 Billion JPY | 4.06% |
| 2012 Q3 | 31.71 Billion JPY | 10.27% |
| 2012 Q2 | 28.75 Billion JPY | 2.86% |
| 2012 Q4 | 30.64 Billion JPY | -3.37% |
| 2012 Q1 | 27.95 Billion JPY | -0.07% |
| 2011 Q1 | 27.85 Billion JPY | -2.99% |
| 2011 FY | 114.41 Billion JPY | 3.25% |
| 2011 Q2 | 28.93 Billion JPY | 3.91% |
| 2011 Q3 | 29.64 Billion JPY | 2.45% |
| 2011 Q4 | 27.97 Billion JPY | -5.64% |
| 2010 Q4 | 28.7 Billion JPY | 1.83% |
| 2010 FY | 110.81 Billion JPY | 0.2% |
| 2010 Q1 | 26.21 Billion JPY | 7.89% |
| 2010 Q3 | 28.19 Billion JPY | 1.77% |
| 2010 Q2 | 27.7 Billion JPY | 5.68% |
| 2009 Q4 | 24.29 Billion JPY | -10.6% |
| 2009 Q2 | 29.82 Billion JPY | 1.77% |
| 2009 Q3 | 27.17 Billion JPY | -8.87% |
| 2009 Q1 | 29.3 Billion JPY | 23.08% |
| 2009 FY | 110.59 Billion JPY | 8.83% |
| 2008 Q2 | 26.75 Billion JPY | 0.0% |
| 2008 FY | 101.61 Billion JPY | -1.72% |
| 2008 Q4 | 23.8 Billion JPY | -6.97% |
| 2008 Q3 | 25.59 Billion JPY | -4.34% |
| 2007 FY | 103.39 Billion JPY | 2.89% |
| 2006 FY | 100.48 Billion JPY | 2.12% |
| 2005 FY | 98.39 Billion JPY | 6.15% |
| 2004 FY | 92.69 Billion JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Kyowa Kirin Co., Ltd. | 442.23 Billion JPY | 31.718% |
| Astellas Pharma Inc. | 1603.67 Billion JPY | 81.17% |
| Chugai Pharmaceutical Co., Ltd. | 1111.36 Billion JPY | 72.829% |
| Ono Pharmaceutical Co., Ltd. | 502.67 Billion JPY | 39.928% |
| JCR Pharmaceuticals Co., Ltd. | 42.87 Billion JPY | -604.357% |
| Daiichi Sankyo Company, Limited | 1601.68 Billion JPY | 81.147% |
| Otsuka Holdings Co., Ltd. | 2018.56 Billion JPY | 85.041% |
| Perseus Proteomics Inc. | 100.4 Million JPY | -300655.961% |